Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy

   Withdrawn · Phase 4 · Renal Disease

   NCT04080076 · Mallinckrodt Hospital Products Inc. · 1 U.S. investigator

   $170,700research payments

2. Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

   Terminated · Phase 1, Phase 2 · Advanced Soft Tissue Sarcoma

   NCT03660930 · Aadi Bioscience, Inc. · 1 U.S. investigator

   $170,087research payments

3. Activity Monitoring in Pulmonary Hypertension

   Active, not recruiting · Pulmonary Hypertension

   NCT04101630 · United Therapeutics Corporation · 2 U.S. investigators

   $170,000research payments

4. Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

   Terminated · Phase 2 · Hidradenitis

   NCT06118099 · Sanofi US Services Inc. · 10 U.S. investigators

   $169,322research payments

5. Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

   Completed · Phase 4 · Hereditary Angioedema

   NCT06806657 · Csl Behring · 5 U.S. investigators

   $168,962research payments

6. A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

   Active, not recruiting · Phase 3 · Follicular Lymphoma (FL)

   NCT06097364 · Regeneron Pharmaceuticals, Inc. · 10 U.S. investigators

   $168,633research payments

7. A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

   Recruiting · Phase 2 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

   NCT06798012 · Takeda Pharmaceuticals U.S.A., Inc. · 6 U.S. investigators

   $168,272research payments

8. Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

   Completed · Phase 2 · Multiple Myeloma

   NCT03361748 · Celgene Corporation · 5 U.S. investigators

   $168,008research payments

9. Randomized Blinded Evaluation of the Effects of TENS and IFC Compared to a Sham Device and SOC in Patients With Non-Specific CLBP

   Completed · Not applicable · Non-Specific Chronic Lower Back Pain

   NCT05972889 · Zynex Medical, Inc. · 1 U.S. investigator

   $167,774research payments

10. Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

    Completed · Phase 3 · Myelofibrosis (MF)

    NCT04472598 · AbbVie Inc. · 17 U.S. investigators

    $167,755research payments

11. Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

    Approved for marketing · Fabry Disease

    NCT04552691 · Chiesi USA, Inc. · 4 U.S. investigators

    $167,740research payments

12. Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

    Active, not recruiting · Phase 2 · Type 1 Diabetes Mellitus

    NCT06812988 · Sanofi US Services Inc. · 7 U.S. investigators

    $167,602research payments

13. A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

    Active, not recruiting · Phase 1 · Juvenile Idiopathic Arthritis (JIA)

    NCT03725007 · AbbVie Inc. · 6 U.S. investigators

    $167,439research payments

14. A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

    Active, not recruiting · Phase 4 · Cardiomyopathy, Hypertrophic

    NCT06112743 · E.r. Squibb & Sons, L.l.c. · 8 U.S. investigators

    $167,352research payments

15. A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

    Terminated · Phase 1, Phase 2 · Methylmalonic Acidemia

    NCT04899310 · ModernaTX, Inc. · 3 U.S. investigators

    $167,012research payments

16. Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

    Terminated · Phase 1 · Chronic Lymphocytic Leukemia

    NCT02200848 · AbbVie Inc. · 1 U.S. investigator

    $166,908research payments

17. Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

    Active, not recruiting · Phase 1 · Primary Central Nervous System Lymphoma

    NCT02203526 · AbbVie Inc. · 1 U.S. investigator

    $166,908research payments

18. Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

    Terminated · Phase 1 · Healthy Participants

    NCT06916143 · Eli Lilly and Company · 2 U.S. investigators

    $166,463research payments

19. Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

    Completed · Phase 2 · Systemic Lupus Erythematosus

    NCT03920267 · E.r. Squibb & Sons, L.l.c. · 19 U.S. investigators

    $166,210research payments

20. An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

    Recruiting · Chronic Kidney Disease (CKD)

    NCT05106387 · Regeneron Pharmaceuticals, Inc. · 6 U.S. investigators

    $165,178research payments

21. Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

    Enrolling by invitation · Not applicable · Coronary Artery Disease

    NCT04451044 · Philips North America LLC · 17 U.S. investigators

    $164,927research payments

22. EFS of Bioabsorbable Implant for NSD

    Completed · Not applicable · Nasal Septal Deviation

    NCT05967169 · Spirair, Inc. · 3 U.S. investigators

    $163,582research payments

23. Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

    Active, not recruiting · Phase 2 · Bipolar I or II Disorder

    NCT07220460 · AbbVie Inc. · 41 U.S. investigators

    $163,544research payments

24. A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

    Completed · Phase 3 · Hepatocellular Carcinoma

    NCT04039607 · E.r. Squibb & Sons, L.l.c. · 9 U.S. investigators

    $162,967research payments

25. A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

    Completed · Phase 3 · Psoriatic Arthritis

    NCT04009499 · UCB SA · 18 U.S. investigators

    $161,498research payments

26. A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT06973187 · Beone Medicines Ltd. · 4 U.S. investigators

    $161,297research payments

27. Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

    Status unknown · Phase 4 · Uveitis, Posterior

    NCT05322070 · Ani Pharmaceuticals, Inc. · 14 U.S. investigators

    $161,074research payments

28. A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

    Active, not recruiting · Phase 3 · Alzheimer Disease

    NCT05508789 · Eli Lilly and Company · 0 U.S. investigators

    $160,810research payments

29. Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

    Active, not recruiting · Phase 2 · Advanced Cancer

    NCT05853575 · E.r. Squibb & Sons, L.l.c. · 4 U.S. investigators

    $160,763research payments

30. Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

    Terminated · Phase 1 · Acute Myelogenous Leukemia

    NCT02203773 · AbbVie Inc. · 1 U.S. investigator

    $160,500research payments

31. A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

    Terminated · Phase 2 · Atopic Dermatitis

    NCT05911841 · Eli Lilly and Company · 10 U.S. investigators

    $159,550research payments

32. A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

    Completed · Phase 2 · Lipoprotein Disorder

    NCT05565742 · Eli Lilly and Company · 9 U.S. investigators

    $159,519research payments

33. A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

    Completed · Phase 3 · Systemic Lupus Erythematosus

    NCT04294667 · UCB SA · 19 U.S. investigators

    $159,300research payments

34. NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

    Recruiting · Phase 1 · Advanced Small Intestine Cancer

    NCT07060014 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $159,055research payments

35. Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

    Active, not recruiting · Phase 2 · Multiple Myeloma

    NCT02899052 · AbbVie Inc. · 11 U.S. investigators

    $158,873research payments

36. A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

    Recruiting · Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)

    NCT06746883 · La Jolla Pharmaceutical Company · 7 U.S. investigators

    $158,795research payments

37. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

    Terminated · Phase 3 · Episodic Migraine

    NCT05028569 · AbbVie Inc. · 26 U.S. investigators

    $158,041research payments

38. Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever

    Completed · Not applicable · Ischemic Stroke

    NCT05152524 · Rapid Medical Ltd · 3 U.S. investigators

    $157,789research payments

39. A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

    Terminated · Phase 1 · Healthy Volunteer

    NCT06579300 · AbbVie Inc. · 1 U.S. investigator

    $157,749research payments

40. Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

    Completed · Phase 2 · Spinal Cord Injury (SCI)

    NCT04295538 · AbbVie Inc. · 12 U.S. investigators

    $157,578research payments

41. Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

    Recruiting · Phase 1, Phase 2 · Plasma Cell Myeloma Refractory

    NCT04643002 · Sanofi US Services Inc. · 5 U.S. investigators

    $156,235research payments

42. Blood Purification for the Treatment of Pathogen Associated Shock

    Active, not recruiting · Not applicable · Septic Shock

    NCT05011656 · Exthera Medical Corporation · 2 U.S. investigators

    $154,966research payments

43. Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

    Terminated · Phase 2 · Amyotrophic Lateral Sclerosis

    NCT05237284 · Genzyme Corporation · 8 U.S. investigators

    $154,548research payments

44. A Study of Subcutaneous Injection in Healthy Participants

    Completed · Not applicable · Healthy

    NCT06516913 · Eli Lilly and Company · 1 U.S. investigator

    $152,825research payments

45. A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

    Completed · Phase 3 · Chronic Spontaneous Urticaria

    NCT05526521 · Sanofi US Services Inc. · 7 U.S. investigators

    $152,580research payments

46. BATwire Implant Kit Study

    Terminated · Not applicable · Heart Failure

    NCT04600791 · Cvrx, Inc. · 4 U.S. investigators

    $152,488research payments

47. Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

    Terminated · Phase 1 · Advanced Soft-tissue Sarcoma

    NCT04204941 · Epizyme, Inc. · 4 U.S. investigators

    $152,258research payments

48. Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

    Completed · Phase 2 · Ovarian Cancer

    NCT05041257 · AbbVie Inc. · 10 U.S. investigators

    $151,554research payments

49. Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

    Recruiting · Phase 2, Phase 3 · Neurogenic Detrusor Overactivity

    NCT05491525 · Sumitomo Pharma America, Inc. · 10 U.S. investigators

    $151,434research payments

50. AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

    Active, not recruiting · Not applicable · Atrial Fibrillation (AF)

    NCT03732794 · Atricure, Inc. · 14 U.S. investigators

    $151,222research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.